<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663464</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-024</org_study_id>
    <nct_id>NCT04663464</nct_id>
  </id_info>
  <brief_title>Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.</brief_title>
  <official_title>An Open-Label, Randomized, 2-Cohort, 2-Period Crossover Pharmacokinetic Study of Abaloparatide-SC and Abaloparatide-sMTS in Healthy Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate and compare the PK profiles of abaloparatide-SC 80 μg and&#xD;
      abaloparatide-sMTS 300 μg in a cohort of healthy men and to make a similar evaluation in a&#xD;
      cohort of healthy women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate and compare the pharmacokinetic (PK) profiles of abaloparatide-SC&#xD;
      80 μg injected subcutaneously into the periumbilical region of the abdomen, and&#xD;
      abaloparatide-sMTS 300 μg applied to the thigh for 5 minutes in a cohort of healthy men and&#xD;
      to make a similar evaluation in a cohort of healthy women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">March 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In each of 2 study periods, subjects received receive either a transdermal patch containing 300 μg abaloparatide for 5 minutes or an injection of abaloparatide SC 80 μg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK Cmax</measure>
    <time_frame>Time frame for collection of PK data after each single-dose administration, separated by 48 hours</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK AUC1</measure>
    <time_frame>Time frame for collection of PK data after each single-dose administration, separated by 48 hours</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC 0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK AUC2</measure>
    <time_frame>Time frame for collection of PK data after each single-dose administration, separated by 48 hours</time_frame>
    <description>AUC from time 0 extrapolated to time infinity (AUC 0-∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects with AEs and SAEs</measure>
    <time_frame>10 Days</time_frame>
    <description>Subjects with treatment-emergent AEs and SAEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>abaloparatide-SC (Period 1) followed by abaloparatide-sMTS (Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abaloparatide-SC injection (Period 1) followed by abaloparatide-sMTS application (Period 2). Abaloparatide-SC is a drug-device combination product consisting of abaloparatide, an active synthetic peptide analog of parathyroid hormone related peptide (PTHrP), administered to the periumbilical region via an injection pen. Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abaloparatide-sMTS (Period 1) followed by abaloparatide-SC (Period 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abaloparatide-sMTS (Period 1) application followed by Abaloparatide-SC injection (Period 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>abaloparatide-sMTS</intervention_name>
    <description>Single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes</description>
    <arm_group_label>Abaloparatide-sMTS (Period 1) followed by abaloparatide-SC (Period 2)</arm_group_label>
    <arm_group_label>abaloparatide-SC (Period 1) followed by abaloparatide-sMTS (Period 2)</arm_group_label>
    <other_name>BA058; abaloparatide-sMTS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>abaloparatide-SC</intervention_name>
    <description>Single-dose administration of abaloparatide 80 μg subcutaneous injection to the periumbilical region of the abdomen</description>
    <arm_group_label>Abaloparatide-sMTS (Period 1) followed by abaloparatide-SC (Period 2)</arm_group_label>
    <arm_group_label>abaloparatide-SC (Period 1) followed by abaloparatide-sMTS (Period 2)</arm_group_label>
    <other_name>BA058; abaloparatide-SC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male and female subjects aged 40 to 65 years old, inclusive, at Screening;&#xD;
&#xD;
          -  Good general health as determined by medical history and physical exam (including&#xD;
             vital signs, and has a body mass index between 18 and 32 kg/m^2;&#xD;
&#xD;
          -  Laboratory test results within the normal range&#xD;
&#xD;
          -  Serum 25-hydroxyvitamin D values must be &gt; 20 ng/mL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of any disorder that may prevent the successful completion of the&#xD;
             study;&#xD;
&#xD;
          -  Diagnosed with osteoporosis, Paget's disease, or other metabolic bone diseases (eg,&#xD;
             vitamin D deficiency or osteomalacia), or had a non-traumatic fracture within 1 year&#xD;
             prior to the initial screening;&#xD;
&#xD;
          -  History of any cancer within the past 5 years other than squamous or basal cell&#xD;
             carcinoma;&#xD;
&#xD;
          -  History of allergy to abaloparatide or drugs in a similar pharmacological class;.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>transdermal delivery</keyword>
  <keyword>solid microstructured transdermal system</keyword>
  <keyword>abaloparatide</keyword>
  <keyword>TYMLOS®</keyword>
  <keyword>abaloparatide-SC</keyword>
  <keyword>abaloparatide-sMTS</keyword>
  <keyword>PK</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abaloparatide</mesh_term>
    <mesh_term>Parathyroid Hormone-Related Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

